NEW ENGLAND JOURNAL OF MEDICINE, cilt.388, sa.16, ss.1533-1534, 2023 (SCI-Expanded, Scopus)
Nirsevimab to Prevent RSV Illness in InfantsNirsevimab, a monoclonal antibody targeting respiratory syncytial virus, protected against RSV-associated hospitalization and severe lower respiratory tract infection in term and late-preterm infants.